Practical AI for CEOs

The AI race is on. CEOs recognise it as the new force multiplier. AI has the potential to both reshape productivity and drive commercial effectiveness. This report by Criticaleye Partner AlixPartners provides a guide to help manage an array of competing stakeholder demands and develop your understanding and capabilities.
 
Key Takeaways Include:
  • Your data is one of your most valuable assets - make it work for you.
  • A fear of missing out and a herd mentality can disproportionately influence technology investments in the current market, potentially leading to poor returns.
  • Deep experience in dealing with business problems, combined with AI insights, drives the kind of actionable results that customers demand.




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
The AI-led HR Revolution at V...

Victrex’s Group HR Director Jilly Atherton has brought together talent planning, leadership development and digital innovation to support a fast-changing global business, using AI where it adds real value without ...

Click here to download this insight
Inside the Take-private at Pr...

After a whirlwind journey from the NYSE to private ownership, PropertyGuru CFO Joe Dische reflects on making the hard calls. In this interview with Criticaleye Senior Editor Bridgette Hall, he discusses public vs privat...

Inspiring Leaders Podcast: Le...

Rob Hornby, Co-CEO of AlixPartners and Rita Clifton CBE, Portfolio Chair and Non-Executive Director (including Deputy Chair of the John Lewis Partnership, Chair of Simplyhealth, Chair of the international sustainability...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 444




E.ON UK AlixPartners Workday Worldpay FTSE Women Leaders Review IBM Consulting Salesforce Legal & General Accenture Google NATS Hitachi Solutions British Land Aldermore Group Drax Group plc Concentrix London Stock Exchange Group Lightsource bp NatWest Group Eightfold AI Palo Alto Networks Rolls-Royce GlaxoSmithKline plc